Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease

作者
Ping‐Hsun Wu,Ming‐Yen Lin,Teng-Hui Huang,Tien‐Ching Lee,Sung‐Yen Lin,Chung‐Hwan Chen,Mei‐Chuan Kuo,Yi‐Wen Chiu,Jer‐Ming Chang,Shang‐Jyh Hwang
出处
期刊:Journal of Personalized Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:12 (2): 185-185 被引量:6
标识
DOI:10.3390/jpm12020185
摘要

Denosumab is approved for osteoporosis treatment in subjects with and without chronic kidney disease (CKD). Confirmation is required for its safety, treatment adherence, renal function effect, and mortality in patients with CKD. A retrospective cohort study was conducted to compare new users of denosumab in terms of their two-year drug adherence in all participants (overall cohort) and CKD participants (CKD subcohort), which was defined as baseline estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2. The eGFR was calculated using the 2021 CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. We defined high adherence (HA) users as receiving three or four doses and low adherence (LA) users as receiving one or two doses. All-cause mortality was analyzed using Kaplan–Meier curves and Cox regression models. In total, there were 1142 subjects in the overall cohort and 500 subjects in the CKD subcohort. HA users had better renal function status at baseline than LD users in the overall cohort. A decline in renal function was only observed among LD users in the overall cohort. In the CKD subcohort, no baseline renal function difference or renal function decline was demonstrated. The all-cause mortality rate of HA users was lower than LA users in both the overall cohort and CKD. A randomized control trial is warranted to target this unique population to confirm our observations.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZY发布了新的文献求助10
1秒前
lxy完成签到 ,获得积分10
1秒前
1秒前
92567发布了新的文献求助10
2秒前
东山发布了新的文献求助10
2秒前
朱俊燕完成签到 ,获得积分10
2秒前
wangjiadong完成签到,获得积分10
3秒前
领导范儿的应助被jia采纳,获得10
4秒前
222完成签到,获得积分20
4秒前
5秒前
5秒前
莫望发布了新的文献求助10
5秒前
aaaaa发布了新的文献求助30
5秒前
缓慢采柳完成签到,获得积分10
5秒前
飞行员完成签到,获得积分20
5秒前
昵猜发布了新的文献求助10
5秒前
Jjj完成签到,获得积分10
5秒前
5秒前
小航2025发布了新的文献求助10
6秒前
xxxxxu完成签到,获得积分10
6秒前
忧虑的寄真完成签到,获得积分10
6秒前
郝丽伟发布了新的文献求助10
6秒前
mingxuan发布了新的文献求助10
6秒前
顾矜的应助被科研通管家采纳,获得10
6秒前
思源的应助被科研通管家采纳,获得10
6秒前
7秒前
7秒前
7秒前
pluto的应助被科研通管家采纳,获得10
7秒前
酷波er的应助被科研通管家采纳,获得10
7秒前
小松弟的应助被科研通管家采纳,获得10
7秒前
李健的应助被科研通管家采纳,获得10
7秒前
充电宝的应助被科研通管家采纳,获得10
7秒前
酷波er的应助被科研通管家采纳,获得30
8秒前
星辰大海的应助被月牙儿采纳,获得10
8秒前
zjy完成签到,获得积分10
8秒前
pluto的应助被科研通管家采纳,获得10
8秒前
无花果的应助被科研通管家采纳,获得10
8秒前
丘比特的应助被科研通管家采纳,获得10
8秒前
Jasper的应助被科研通管家采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124